Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Further, an upregulation of PD-1 on sTILs of residual disease and a decline ... patients with treatment-naïve nonmetastatic HER2-positive breast cancer. Patients needed to have an Easter ...

The KATHERINE trial included 1,486 patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer who had residual invasive disease in the breast or axillary lymph node ...

Launched in 2012, the multinational KATHERINE trial involved almost 1,500 women with HER2-positive breast cancer and residual disease in the breast or axillary lymph nodes after neoadjuvant ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer: Final 10-Year Analysis of the Open-Label, Single-Arm, Phase 2 APT Trial Trastuzumab Emtansine for Residual ...

An early-stage HER2-positive (HER2+) breast cancer is always a shock, but today’s treatment options should give you hope. Over the past 2 decades, advances in medicine have brought us new ...

Residual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy (NAC) had a higher ...

HER2-positive breast cancer ... However, if a patient still has cancer cells at the time of surgery or residual cancer are identified after surgery, there are additional treatment options available to ...

I think in HER2+ breast cancer ... triple-negative breast cancer where there's residual disease; that's a trickier problem. That's a place where if you detect something, it may be there, it ...

Please provide your email address to receive an email when new articles are posted on . Adjuvant ado-trastuzumab emtansine improved survival compared with trastuzumab for early HER2-positive ...